AstraZeneca Asks Judge To Bar Use Of Fintiv Rule In PGRs
Pharmaceutical giant AstraZeneca is the latest to say the Patent Trial and Appeal Board's policy of rejecting patent reviews based on district court litigation violates the law, arguing in a new...To view the full article, register now.
Already a subscriber? Click here to view full article